Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 12, 2015, Pages 2129-2135

  Shea, Thomas C ^a   Walko, Christine ^b   Chung, Yunro ^c   Ivanova, Anastasia ^a,c   Sheets, Julia ^a   Rao, Kamakshi ^a   Gabriel, Don ^a   Comeau, Terry ^d   Wood, William ^a   Coghill, James ^a   Armistead, Paul ^a   Sarantopoulos, Stefanie ^e   Serody, Jonathan ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c IL   (United States)

^d St John's Regional Hospital   (Canada)

^e DUKE UNIVERSITY   (United States)

Author keywords

Allogeneic; Busulfan; Dose escalation; Pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLEARANCE AT STEADY-STATE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LIVER FAILURE; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RASH; RECURRENCE FREE SURVIVAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADULT; AREA UNDER CURVE; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84947489995     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.016     Document Type: Article

References (35)

1. Gooley T., Chien M.D., Pergam S., et al. Reduced mortality after allogeneic stem cell transplantation. N Engl J Med 2010, 363:2091-2101.
2. Hahn T., McCarthy P., Hassebroek A., et al. Significant improvements in survival after allogeneic stem cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
3. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
4. Kanate A.S., Pasquini M.C., Hari P.N., Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: current state in 2013 and future directions. World J Stem Cells 2014, 6:69-81.
5. Horan J.T., Logan B.R., Agovi-Johnson M.A., et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. J Clin Oncol 2011, 29:805-813.
6. Bejar R., Stevenson K., Caughey B., et al. Somatic mutations predict poor outcomes in patients with myelodysplastic syndrome after hematopoietic stem cell transplantation. J Clin Oncol 2014, 32:2691-2698.
7. Ringden O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
8. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
9. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
10. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
11. Lee S.J., Klein J., Haagenson M., et al. High resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4585.
12. Gragert L., Eapen M., Williams E., et al. HLA match likelihood for hematopoietic stem cell grafts in the U.S. N Engl J Med 2014, 371:339-348.
13. Shimoni A., Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol 2011, 24:369-379.
14. Schlenk R.F., Dohner K., Mack S., et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian Trial AMLHD98A. J Clin Oncol 2010, 28:4642-4648.
15. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
16. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
17. Copelan E.A., Hamilton B.K., Avalos B., et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013, 122:3863-3870.
18. Bredeson C., LeRademacher J., Kato K., et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013, 122:3871-3878.
19. Teicher B.A., Holden S.A., Eder J.P., et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989, 49:5994-5998.
20. Eder J.P., Elias A.D., Ayash L., et al. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol 1991, 29:61-65.
21. Wilson W.H., Grossbard M.L., Pittaluga S., et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002, 99:2685-2693.
22. Barlogie B., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310:1353-1356.
23. ASBMT RFI 2015 - Disease Classifications Corresponding to CIBMTR Classifications. Retrieved from: . http://www.asbmt.org/resource/resmgr/RFI/RFI_2015_CIBMTR_Disease_Cl.pdf.
24. Bearman S.I., Anderson G.L., Mori M., et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993, 11:1729-1736.
25. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft vs. host disease in humans recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
26. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
27. Lindley C., Shea T., McCune J., et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 2004, 15:453-459.
28. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
29. Slattery J.T., Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998, 20:543-549.
30. Chen T.L., Grochow L.B., Hurowitz L.A., et al. Determination of busulfan in human plasma by gas chromatography with electron-capture detection. J Chromatogr 1988, 425:303-309.
31. Ivanova A., Flournoy N., Chung Y. Cumulative cohort design for dose-finding. J Stat Plann Inference 2007, 137:2316-2317.
32. Ivanova A., Qaqish B.F., Schell M.J. Continuous toxicity monitoring in phase II trials in oncology. Biometrics 2005, 61:540-545.
33. Przepiorka D., Ippolii C., Khouri I., et al. Tacrolimus and minidose methotrexate for prevention of acute graft versus host disease after matched unrelated donor transplantation. Blood 1996, 88:4383-4389.
34. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
35. McCune J.S., Gibbs J.P., Slattery J.T. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet 2000, 39:155-165.